top
Search terms
Results 11 - 18 of 18 - ordered by :
Pages: 1 2
Ehjcvp

In this issue of the journal, Dr Vries and co-workers report data from a study that aimed to explore the level of agreement between windows for different platelet function tests (PFTs) used to ...

European Heart Journal - Cardiovascular Pharmacotherapy, Editorials, Stefan Agewall

Date : 01/01/2017 Item size : 132260 bytes
Ehjcvp

A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease Methods and ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLE, D.G. Kallend, J.A.A. Reijers, S.E. Bellibas, A. Bobillier, H. Kempen, J. Burggraaf, M. Moerland, P.L.J. Wijngaard

Date : 01/01/2016
Ehjcvp

Abstract Aims Therapeutic windows for residual platelet reactivity in patients with coronary artery disease on P2Y12 inhibitors were proposed in a consensus document. Conclusions Our results suggest ...

European Heart Journal - Cardiovascular Pharmacotherapy, Original Article, Minka J.A. Vries, Heleen J. Bouman, Renske H. Olie, Leo F. Veenstra, Suzanne Zwaveling, Paul W.M. Verhezen, Arina J. ten ...

Date : 07/09/2016
Ehjcvp

Exploring the potential of low-dose sulfasalazine in stable coronary artery disease patients: randomized, double-blind, placebo-controlled study Recent statistics reports by Centre for Disease ...

European Heart Journal - Cardiovascular Pharmacotherapy, CORRESPONDENCE, Kanchan Vohra, Pawan Krishan, Sudhir Varma, Harpreet Singh Kalra

Date : 01/10/2015
Ehjcvp

Glycoprotein IIb/IIIa receptor inhibitors (GPIs) block the final common pathway leading to platelet aggregation that occurs via the cross-linking of fibrinogen and von Willebrand factor upon exposure ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLES, Jeffrey D. Wessler, Robert P. Giugliano

Date : 01/04/2015
Ehjcvp

While the absolute number of comorbidities such as renal disease, liver disease, chronic obstructive pulmonary disease, and vascular disease has increased, there was a relative decrease of ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIAL, Lorenz Koller, Alexander Niessner

Date : 01/07/2015
Ehjcvp

The aim of this review is to provide an overview of the evidence from randomized, clinical trials and epidemiological studies, with a focus on the optimal duration of dual antiplatelet therapy (DAPT) ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Pierre Sabouret, Sophie K. Rushton-Smith, Mathieu Kerneis, Johanne Silvain, Jean-Philippe Collet, Gilles Montalescot

Date : 01/07/2015
Ehjcvp

Introduction Dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a P2Y12 inhibitor, is recommended by guidelines for up to 12 months in patients with acute coronary ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLE, Gianluigi Savarese, Stefano Savonitto, Lars H. Lund, Stefania Paolillo, Caterina Marciano, Santo Dellegrottaglie, Antonio ...

Date : 21/04/2016